Marked Chart Marked Chart Closed

The Marked Chart Wire · Health

VK2735

Viking Therapeutics initiates phase 3 trial for oral weight-loss tablet

Viking Therapeutics has started a phase 3 clinical trial to test its oral weight-loss tablet.

VKTX-1.3%

Illustration for the Health desk

The stocks in this story

  1. VKTX-1.3%Viking$25.84

Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.

New to this? Read: Reading a stock chart

More Health news

Illustration for the Health desk

Biohaven

Biohaven shares phase 1 results for BHV-1530

Biohaven disclosed early trial data for its antibody-drug conjugate BHV-1530. The findings showed that patients with FGFR3-altered cancers experienced shrinkage of tumors and other clinical benefits.

Fast headlines, summarized. Not verified and not advice. Check the full story before you act.